相关临床试验
87
36 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1860
进行中（未招募）
2
2.3%
已完成
11
12.6%
尚未招募
34
39.1%
招募中
31
35.6%
终止
7
8.1%
撤回
2
2.3%
暂无批准数据
- Data4Life and Monash Health signed a Memorandum of Understanding to optimize clinical trial design, execution, and patient recruitment. - The collaboration combines Monash Health's clinical research expertise with Data4Life's open-source platforms, D4L Collect and Data2Evidence, built on HL7 FHIR and OMOP Common Data Model. - Monash Health, Victoria's largest public health service, maintains 1,600 active studies including 600 first-in-human and phase 2 trials. - The partnership aims to enable federated studies, cross-border comparisons, and reproducible real-world evidence generation while preserving patient privacy.
- Racura Oncology has dosed the first patient in its Phase 1 HARNESS-1 trial evaluating RC220 combined with osimertinib in EGFR-mutant non-small cell lung cancer. - The patient received a 50 mg/m² intravenous infusion of RC220 at Monash Health in Victoria, with no adverse events observed during or after dosing. - The trial employs a staged dose-escalation design using single-patient cohorts before expanding to identify the maximum tolerated dose of the RC220-osimertinib combination. - HARNESS-1 addresses a significant clinical challenge: resistance to current tyrosine kinase inhibitor therapies in patients with EGFR-mutant NSCLC.
- Racura Oncology has received governance approval from Monash Health for its HARNESS-1 Phase 1a/b trial testing RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. - The trial will enroll 12-40 patients using ctDNA screening and Bayesian dose escalation to determine maximum tolerated dose, with site initiation training scheduled for March 23, 2026. - RC220 is an RNA/DNA G4 binder designed to enhance efficacy and safety in combination therapy, addressing resistance to osimertinib in lung cancer patients. - The company maintains $20.94 million in cash through December 2025, providing funding runway through 2027 to support clinical development programs.
- Researchers at Hudson Institute of Medical Research discovered that Pirfenidone, a drug used to treat lung fibrosis, effectively reduces both viral replication and airway inflammation in COPD without suppressing immune response. - The pre-clinical study found Pirfenidone outperformed steroids in managing COPD exacerbations while avoiding the severe side effects associated with long-term steroid use, including diabetes, hypertension, and osteoporosis. - COPD affects approximately 2 million Australians and current steroid treatments create a paradox by reducing inflammation but encouraging viral replication during exacerbations. - The findings, published in the American Journal of Respiratory Cell and Molecular Biology, suggest Pirfenidone could allow patients to discontinue steroids and prevent severe COPD flares that can lead to premature death.
- BioNTech has partnered with Peter MacCallum Cancer Centre to establish a clinical trial platform in Victoria, Australia, aimed at improving access to investigational therapies for hard-to-treat cancers. - The platform creates a network of key delivery partners including Austin Health, Alfred Health, and Monash Health to streamline clinical trials across Melbourne and regional Victoria. - BioNTech is also establishing a state-of-the-art facility in Victoria in partnership with mRNA Vic to support research, development, and clinical-scale manufacturing of mRNA-based medicines. - The initiative leverages Victoria's thriving biomedical ecosystem and world-class cancer survival rates to potentially unlock breakthrough cancer treatments.
- Hudson Institute researchers advance groundbreaking extracellular vesicle treatment derived from amniotic cells into clinical trials for complex perianal Crohn's disease, offering a potential cost-effective alternative to stem cell therapy. - The first-in-human trial will evaluate the safety and efficacy of hAEC-EV therapy in 15 participants with refractory Crohn's perianal fistulas, marking the second human EV trial in Australia. - With the global Crohn's disease market projected to reach $13.4 billion by 2026, this innovative approach could provide a more accessible treatment option for the one-third of patients who develop fistulas.
